Effect of thymosin in vitro on T cell levels during radiation therapy: correlations with radiation portal and initial T cell levels.
The effect of thymosin in vitro on percent T cells was determined in 388 blood specimens from patients with head and neck, mediastinal, and pelvic malignancies during radiation therapy, in 94 untreated patients with these malignancies, and 277 normal adults. Changes in percent T cell levels after incubation of lymphocytes with thymosin did not correlate with tumor histology or cumulative radiation dose, but in all groups correlated with radiation portal and initial T cell levels. T cell levels increased by a similar increment in normals and in the untreated patients. During irradiation, the mean levels after incubation with thymosin did not change in patients with head and neck and pelvic malignancies, but in patients with mediastinal malignancies the levels increased significantly more than in normals. For a given T cell level, the increase in patients with mediastinal malignancies was greater than in patients with pelvic malignancies, and as a group was greater than in patients with head and neck malignancies. The results can be explained by an increase in circulating thymosin-responsive lymphocytes during mediastinal irradiation due to suppression of a function of the thymus important for maturation of these cells, and a decrease in these cells during pelvic irradiation due to a deleterious effect on precursors in pelvic bone marrow. The results thus provide a rationale for clinical trials to assess the efficacy of thymosin in averting declines of T cell levels in patients receiving mediastinal irradiation.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006258:Head and Neck Neoplasms / Q000276:immunology / Q000532:radiotherapy; D006801:Humans; D066298:In Vitro Techniques; D007958:Leukocyte Count; D008297:Male; D008479:Mediastinal Neoplasms / Q000276:immunology / Q000532:radiotherapy; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy*; D010386:Pelvic Neoplasms / Q000276:immunology / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D013601:T-Lymphocytes / Q000187:drug effects* / Q000528:radiation effects; D013947:Thymosin / Q000494:pharmacology*; D013951:Thymus Hormones / Q000494:pharmacology*
D013951:Thymus Hormones; D013947:Thymosin